|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
66,230,000 |
Market
Cap: |
4.11(M) |
Last
Volume: |
362,100 |
Avg
Vol: |
361,116 |
52
Week Range: |
$0.062 - $0.062 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Rosenblum Mark J |
Chief Financial Officer |
|
2014-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
530 |
113,822 |
|
- |
|
French Christy Lee |
Exec. Dir. of Medical Affairs |
|
2014-01-31 |
4 |
D |
$4.49 |
$189 |
D/D |
(42) |
77,935 |
|
- |
|
French Christy Lee |
Exec. Dir. of Medical Affairs |
|
2014-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
265 |
77,977 |
|
- |
|
Mayes Gregory T. |
Cheif Operating Officer |
|
2014-01-07 |
4/A |
D |
$4.03 |
$6,307 |
D/D |
(1,565) |
131,828 |
|
- |
|
Mayes Gregory T. |
Cheif Operating Officer |
|
2014-01-07 |
4/A |
A |
$0.00 |
$0 |
D/D |
2,985 |
133,393 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2014-01-07 |
4 |
D |
$4.03 |
$33,546 |
D/D |
(8,324) |
116,810 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
125,134 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-01-07 |
4 |
D |
$4.03 |
$73,185 |
D/D |
(18,160) |
312,814 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-01-07 |
4 |
D |
$4.03 |
$73,185 |
D/D |
(18,160) |
312,814 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
330,974 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
330,974 |
|
- |
|
French Christy Lee |
Exec. Dir. of Medical Affairs |
|
2014-01-07 |
4 |
D |
$4.03 |
$25,159 |
D/D |
(6,243) |
77,712 |
|
- |
|
French Christy Lee |
Exec. Dir. of Medical Affairs |
|
2014-01-07 |
4 |
D |
$4.03 |
$25,159 |
D/D |
(6,243) |
77,712 |
|
- |
|
French Christy Lee |
Exec. Dir. of Medical Affairs |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
83,955 |
|
- |
|
Rosenblum Mark J |
Chief Financial Officer |
|
2014-01-07 |
4 |
D |
$4.03 |
$33,546 |
D/D |
(8,324) |
113,292 |
|
- |
|
Rosenblum Mark J |
Chief Financial Officer |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
121,616 |
|
- |
|
French Christy Lee |
Exec. Dir. of Medical Affairs |
|
2014-01-07 |
4 |
D |
$4.03 |
$13,110 |
D/D |
(3,253) |
8,955 |
|
- |
|
French Christy Lee |
Exec. Dir. of Medical Affairs |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
6,203 |
12,208 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2014-01-07 |
4 |
D |
$4.03 |
$6,307 |
D/D |
(1,565) |
151,420 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
2,985 |
152,985 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-01-07 |
4 |
D |
$4.03 |
$16,414 |
D/D |
(4,073) |
80,974 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
10,825 |
85,048 |
|
- |
|
Rosenblum Mark J |
Chief Financial Officer |
|
2014-01-07 |
4 |
D |
$4.03 |
$6,307 |
D/D |
(1,565) |
21,616 |
|
- |
|
Rosenblum Mark J |
Chief Financial Officer |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
2,985 |
23,181 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2014-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
8,847 |
25,134 |
|
- |
|
586 Records found
|
|
Page 20 of 24 |
|
|